Welcome to our dedicated page for Shuttle Pharmaceuticals Holdings SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Shuttle Pharmaceuticals Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Shuttle Pharmaceuticals Holdings's regulatory disclosures and financial reporting.
HRT Financial LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported selling a total of 29,111 shares of common stock in early July. It sold 18,531 shares on July 8 at $3.52 per share and 10,580 shares on July 7 at $3.33 per share in open-market transactions.
After these sales, HRT Financial LP directly holds 52,274 shares of Shuttle Pharmaceuticals common stock. The filing shows straightforward open-market sales with no derivative exercises or related derivative positions reported.
Shuttle Pharmaceuticals Holdings, Inc. reported that significant shareholder HRT Financial LP made offsetting trades in its common stock. On July 2, HRT Financial LP executed an open-market purchase of 7,851 shares at $3.54 per share. On July 6, it executed an open-market sale of 9,022 shares at $3.51 per share, resulting in a modest net reduction of its position. Following these transactions, HRT Financial LP directly held 81,385 shares of Shuttle Pharmaceuticals common stock.
HRT FINANCIAL LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported an open-market purchase of common stock. On July 1, 2026, it bought 3,959 shares of Shuttle common stock at $3.30 per share. After this transaction, HRT FINANCIAL LP directly owns 82,556 shares of Shuttle common stock.
HRT Financial LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported two open-market purchases of common stock. It bought 25,836 shares at $3.44 per share on June 29 and 6,755 shares at $3.23 per share on June 30. After these trades, HRT Financial LP directly holds 78,597 shares of Shuttle Pharmaceuticals common stock.
HRT Financial LP filed an initial ownership report for Shuttle Pharmaceuticals Holdings, Inc. as a ten percent owner. The filing shows direct ownership of 71,842 shares of Common Stock following the reported date. This Form 3 establishes HRT Financial LP’s starting equity position as a large shareholder.
Shuttle Pharmaceuticals Holdings’ wholly owned subsidiary United Dogecoin Inc. is advancing its Dogecoin mining and digital infrastructure strategy. The Company is evaluating proprietary data centre and behind-the-meter power generation opportunities in Idaho and Alberta to support long-term DOGE mining and future AI and high-performance computing workloads.
United Dogecoin has purchased its first fleet of ElphaPex DG1+ mining units, each delivering 14.4 GH/s, and expects them to be deployed and fully operational within approximately 60 days, subject to delivery and installation. It has also secured a renewable, hydroelectric-powered data centre site providing energy at US$0.064 per kilowatt hour, which is intended to underpin low-cost, scalable mining operations and potential third-party AI hosting services.
Shuttle Pharmaceuticals Holdings, Inc. implemented a one-for-ten reverse stock split of its common stock, effective at the start of trading on June 11, 2026. Every ten shares of common stock outstanding before the effective time were automatically reclassified into one share, with no change to the par value.
The reverse split proportionally adjusted the share amounts and exercise or conversion prices of outstanding warrants, restricted stock units, and convertible preferred stock, while leaving the total authorized common and preferred share counts unchanged. No fractional shares were issued; holders entitled to a fraction received one full post-split share instead. Trading on the Nasdaq Capital Market continued on a split-adjusted basis under a new CUSIP number.
Shuttle Pharmaceuticals Holdings, Inc. filed an initial Form 3 for Co-Chief Executive Officer Ryan Trasolini. The filing reports his status as an officer of the company but does not list any specific share holdings or recent transactions in company securities.
Shuttle Pharmaceuticals Holdings, Inc. held its 2026 annual stockholder meeting, with 3,375,072 shares of common stock represented out of 5,546,309 shares outstanding as of March 25, 2026, establishing a quorum of approximately 60.85%.
Stockholders elected four directors—Christopher Cooper, Adam Chambers, George Scorsis, and Angel Liriano—to serve until the 2027 annual meeting. They also ratified Forvis Mazars, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved on an advisory basis the executive compensation program described in the proxy statement.
Stockholders authorized the board to implement one or more reverse stock splits of the common stock at ratios between 1-for-2 and 1-for-150 at the board’s discretion. A proposal to adjourn the meeting was also approved, although it was ultimately not needed because a quorum was present and all other proposals had sufficient support.
Shuttle Pharmaceuticals Holdings, Inc. reported a net loss of about $2.2 million for the three months ended March 31, 2026, with no revenue and a working capital deficit of approximately $5.8 million. Cash and cash equivalents were $1.09 million, leaving the company dependent on external financing.
In March 2026 Shuttle raised gross proceeds of $3.5 million through an underwritten offering of 2,238,800 common shares and 4,761,200 pre-funded warrants. Management states that existing resources, recent equity raises and a revolving note are still insufficient to fund operations for the next twelve months, and the filing notes substantial doubt about the company’s ability to continue as a going concern.